OmniAb, Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. By leveraging its proprietary technologies and platforms, the company aims to generate a diverse array of high-quality antibodies for various therapeutic applications, focusing primarily on areas such as oncology, autoimmune diseases, and infectious diseases. OmniAb collaborates with other biotechnology and pharmaceutical companies to enhance drug discovery processes, ultimately seeking to advance innovative treatments that can address unmet medical needs. Read More
OmniAb, Inc. (NASDAQ: OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time.
OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors (“Viking”).
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2025, after the close of the U.S. financial markets on Tuesday, November 4, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. Management will be available for one-on-one meetings on Tuesday, September 9th with investors registered for the event.
OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any placement agent fees and offering-related expenses. The net proceeds from the financing are expected to be used by OmniAb for general corporate purposes. The private placement is expected to close on or about August 26, 2025, subject to customary closing conditions.
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Wednesday, August 6, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
OmniAb, Inc. (NASDAQ: OABI) today announced its participation in the 21st Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today, the company showcased case studies utilizing xPloration, a high-throughput single B-cell screening platform that harnesses machine learning and computer vision artificial intelligence (AI), in a presentation by Bob Chen, Ph.D., Vice President, Discovery Systems, titled “xPloration: Simplifying Deep Antibody Mining for Maximum Impact.”
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and development. xPloration is OmniAb’s proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence.
OmniAb, Inc. (NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb’s partnership base. These Board changes are effective immediately and increase the number of Directors to seven.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
